Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

2.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S.

Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17. Review.

3.

Human viral oncogenesis: a cancer hallmarks analysis.

Mesri EA, Feitelson MA, Munger K.

Cell Host Microbe. 2014 Mar 12;15(3):266-82. doi: 10.1016/j.chom.2014.02.011. Review.

4.

The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease.

Feitelson MA, Bonamassa B, Arzumanyan A.

Expert Opin Ther Targets. 2014 Mar;18(3):293-306. doi: 10.1517/14728222.2014.867947. Epub 2014 Jan 3. Review.

PMID:
24387282
5.

Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.

Wu G, Liu B, Zhang Y, Li J, Arzumanyan A, Clayton MM, Schinazi RF, Wang Z, Goldmann S, Ren Q, Zhang F, Feitelson MA.

Antimicrob Agents Chemother. 2013 Nov;57(11):5344-54. doi: 10.1128/AAC.01091-13. Epub 2013 Aug 19.

6.

UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.

Wu G, Lin N, Xu L, Liu B, Feitelson MA.

BMC Cancer. 2013 Mar 28;13:167. doi: 10.1186/1471-2407-13-167. Erratum in: BMC Cancer. 2014;14:216. Feitelson, Mark A [added].

7.

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Arzumanyan A, Reis HM, Feitelson MA.

Nat Rev Cancer. 2013 Feb;13(2):123-35. doi: 10.1038/nrc3449. Review.

PMID:
23344543
8.

A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture.

Brown ZZ, Akula K, Arzumanyan A, Alleva J, Jackson M, Bichenkov E, Sheffield JB, Feitelson MA, Schafmeister CE.

PLoS One. 2012;7(10):e45948. doi: 10.1371/journal.pone.0045948. Epub 2012 Oct 18.

9.

Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein.

Arzumanyan A, Sambandam V, Clayton MM, Choi SS, Xie G, Diehl AM, Yu DY, Feitelson MA.

Cancer Res. 2012 Nov 15;72(22):5912-20. doi: 10.1158/0008-5472.CAN-12-2329. Epub 2012 Sep 17.

10.

Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA.

Antimicrob Agents Chemother. 2012 Dec;56(12):6186-91. doi: 10.1128/AAC.01483-12. Epub 2012 Sep 17.

11.

Role of miR-148a in hepatitis B associated hepatocellular carcinoma.

Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA.

PLoS One. 2012;7(4):e35331. doi: 10.1371/journal.pone.0035331. Epub 2012 Apr 9.

12.

Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer.

Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z, Feitelson MA.

Oncogene. 2012 Feb 2;31(5):563-72. doi: 10.1038/onc.2011.255. Epub 2011 Jun 27.

13.

Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?

Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA.

Cancer Res. 2011 May 15;71(10):3701-8. doi: 10.1158/0008-5472.CAN-10-3951. Epub 2011 Apr 4.

14.

Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC.

Wang W, Zhao LJ, Wang Y, Tao QY, Feitelson MA, Zhao P, Ren H, Qi ZT.

Cancer Biomark. 2011-2012;11(1):29-39. doi: 10.3233/CBM-2012-0261.

PMID:
22820138
15.

Oxidative stress and antioxidants in hepatic pathogenesis.

Ha HL, Shin HJ, Feitelson MA, Yu DY.

World J Gastroenterol. 2010 Dec 28;16(48):6035-43. Review.

16.

Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.

Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, Hua X, Chen Z, Ding H, Gao L, Wang Y, Feitelson MA, Zhao P, Qi ZT.

J Virol. 2011 Mar;85(6):2793-802. doi: 10.1128/JVI.01818-10. Epub 2010 Dec 22.

17.

Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma.

Fan R, Li X, Du W, Zou X, Du R, Zhao L, Luo G, Mo P, Xia L, Pan Y, Shi Y, Lian Z, Feitelson MA, Nie Y, Liu J, Fan D.

Int J Cancer. 2011 Jun 15;128(12):2980-93. doi: 10.1002/ijc.25624. Epub 2010 Oct 8.

18.

RNA interference-mediated URG4 gene silencing diminishes cyclin D1 mRNA expression in HepG2 cells.

Satiroglu-Tufan NL, Dodurga Y, Gok D, Cetinkaya A, Feitelson MA.

Genet Mol Res. 2010 Aug 10;9(3):1557-67. doi: 10.4238/vol9-3gmr872.

19.

Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer.

Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, Feitelson MA.

Int J Cancer. 2009 Oct 15;125(8):1894-901. doi: 10.1002/ijc.24580.

20.

Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis.

Cao W, Sun B, Feitelson MA, Wu T, Tur-Kaspa R, Fan Q.

Int J Cancer. 2009 Jun 15;124(12):2886-92. doi: 10.1002/ijc.24265.

21.

Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease.

Feitelson MA, Reis HM, Tufan NL, Sun B, Pan J, Lian Z.

Cancer Lett. 2009 Dec 1;286(1):69-79. doi: 10.1016/j.canlet.2008.12.010. Epub 2009 Feb 6. Review.

22.

Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma.

Feitelson MA, Clayton MM, Reis HM, Wu G, Lu EP.

Expert Opin Pharmacother. 2008 Sep;9(13):2233-45. doi: 10.1517/14656566.9.13.2233 . Review.

PMID:
18710349
23.

Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells.

Liu X, Zhang S, Lin J, Zhang S, Feitelson MA, Gao H, Zhu M.

Biochem Biophys Res Commun. 2008 Sep 5;373(4):643-7. doi: 10.1016/j.bbrc.2008.06.087. Epub 2008 Jul 3.

PMID:
18602370
24.

Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.

Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.

Mol Carcinog. 2009 Jan;48(1):56-65. doi: 10.1002/mc.20455.

PMID:
18506760
25.

Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses.

Liu X, Wang L, Zhang S, Lin J, Zhang S, Feitelson MA, Gao H, Zhu M.

Carcinogenesis. 2008 Jun;29(6):1207-14. doi: 10.1093/carcin/bgn111. Epub 2008 May 13.

26.

COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma.

Liu XH, Lin J, Zhang SH, Zhang SM, Feitelson MA, Gao HJ, Zhu MH.

World J Gastroenterol. 2008 Mar 7;14(9):1346-52.

27.

[Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings].

Tong GD, Zhou DQ, He JS, Xiao CL, Liu XL, Zhou XZ, Zhang X, Xing YF, Lü P, Feitelson MA.

Zhonghua Gan Zang Bing Za Zhi. 2007 Nov;15(11):828-32. Chinese.

PMID:
18073065
28.

The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin.

Pan J, Lian Z, Wallett S, Feitelson MA.

J Gen Virol. 2007 Dec;88(Pt 12):3275-85. Erratum in: J Gen Virol. 2008 Mar;89(Pt 3):839. Wallet, Sarah [corrected to Wallett, Sarah].

PMID:
18024896
29.

Efficient induction of mouse immune responses to hepatitis C virus by viral core protein-carrying attenuated Salmonella typhimurium.

Liao XL, Ren H, Zhao P, Zhu SY, Cao J, Chen ZH, Zhao LJ, Pan W, Feitelson MA, Qui ZT.

Viral Immunol. 2007 Sep;20(3):469-78.

PMID:
17931117
30.

Development of a novel mouse model to evaluate drug candidates against hepatitis B virus.

Feitelson MA, Clayton MM, Sun B, Schinazi RF.

Antivir Chem Chemother. 2007;18(4):213-23.

PMID:
17907379
31.

A translational worldwide perspective for liver cancer - First International Meeting.

Feitelson MA.

IDrugs. 2007 Sep;10(9):630-2. No abstract available.

PMID:
17786845
32.

Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis.

Lian Z, Liu J, Wu M, Wang HY, Arbuthnot P, Kew M, Feitelson MA.

Hepatology. 2007 Jun;45(6):1390-9.

PMID:
17539024
33.

Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis.

Feitelson MA, Lee J.

Cancer Lett. 2007 Jul 18;252(2):157-70. Epub 2006 Dec 22. Review.

PMID:
17188425
34.
35.

HEP DART 2005 -- frontiers in drug development for viral hepatitis.

Feitelson MA.

IDrugs. 2006 Mar;9(3):165-7. No abstract available.

PMID:
16523376
36.

Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin.

Lian Z, Liu J, Li L, Li X, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, Fan D, Feitelson MA.

Hepatology. 2006 Mar;43(3):415-24.

PMID:
16496348
37.

Different response requirements for IFNgamma production in ELISPOT assays by CD4+ T cells from mice early and late after immunization.

Chichester JA, Feitelson MA, Calkins CE.

J Immunol Methods. 2006 Feb 20;309(1-2):99-107. Epub 2005 Dec 27.

PMID:
16417908
38.

Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma.

Liu J, Lian Z, Han S, Waye MM, Wang H, Wu MC, Wu K, Ding J, Arbuthnot P, Kew M, Fan D, Feitelson MA.

Oncogene. 2006 Feb 16;25(7):1008-17.

PMID:
16247464
39.

Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma.

Feitelson MA.

Cancer Lett. 2006 Jul 28;239(1):10-20. Epub 2005 Sep 8. Review.

PMID:
16154256
40.

Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma.

Zhu Z, Lin J, Qu JH, Feitelson MA, Ni CR, Li FM, Zhu MH.

World J Gastroenterol. 2005 Apr 7;11(13):1903-9.

41.

Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis.

Feitelson MA, Reis HM, Liu J, Lian Z, Pan J.

Front Biosci. 2005 May 1;10:1558-72. Review.

PMID:
15769646
42.

c-myc overexpression in hepatocarcinogenesis.

Feitelson MA.

Hum Pathol. 2004 Nov;35(11):1299-302. No abstract available.

PMID:
15668885
43.

Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma.

Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini MJ, Feitelson MA.

Cancer Res. 2004 Oct 15;64(20):7329-35.

44.

Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis.

Sun BS, Pan J, Clayton MM, Liu J, Yan X, Matskevich AA, Strayer DS, Gerber M, Feitelson MA.

J Cell Physiol. 2004 Dec;201(3):447-58.

PMID:
15389552
45.

Activation of fibronectin gene expression by hepatitis B virus x antigen.

Norton PA, Reis HM, Prince S, Larkin J, Pan J, Liu J, Gong Q, Zhu M, Feitelson MA.

J Viral Hepat. 2004 Jul;11(4):332-41.

PMID:
15230856
46.

Human S15a expression is upregulated by hepatitis B virus X protein.

Lian Z, Liu J, Li L, Li X, Tufan NL, Wu MC, Wang HY, Arbuthnot P, Kew M, Feitelson MA.

Mol Carcinog. 2004 May;40(1):34-46.

PMID:
15108328
47.

Early molecular and genetic determinants of primary liver malignancy.

Feitelson MA, Pan J, Lian Z.

Surg Clin North Am. 2004 Apr;84(2):339-54. Review.

PMID:
15062649
49.

Detection of hepatitis B virus X antigen by immunohistochemistry and Western blotting.

Liu J, Feitelson MA.

Methods Mol Med. 2004;95:71-84. No abstract available.

PMID:
14762297
50.

Hepatitis B virus transgenic severe combined immunodeficient mouse model of acute and chronic liver disease.

Feitelson MA, Larkin JD, Schinazi RF.

Methods Mol Med. 2004;96:269-87. No abstract available.

PMID:
14762277

Supplemental Content

Loading ...
Support Center